Gene Variant Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Gene NRAS
Variant G115Efs*46
Impact List frameshift
Protein Effect loss of function - predicted
Gene Variant Descriptions NRAS G115Efs*46 indicates a shift in the reading frame starting at amino acid 115 and terminating 46 residues downstream causing a premature truncation of the 189 amino acid Nras protein (UniProt.org). Due to the loss of the CAAX motif (PMID: 6087162, PMID: 21924373), G115Efs*46 is predicted to lead to a loss of Nras protein function resulting in inactivation of downstream signaling.
Associated Drug Resistance
Category Variants Paths

NRAS mutant NRAS exon4 NRAS G115Efs*46

NRAS mutant NRAS inact mut NRAS G115Efs*46

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Transcript NM_002524.5
gDNA chr1:g.114709677delC
cDNA c.344delG
Protein p.G115Efs*46
Source Database RefSeq
Genome Build GRCh38/hg38
Transcript gDNA cDNA Protein Source Database Genome Build
NM_002524.4 chr1:g.114709677delC c.344delG p.G115Efs*46 RefSeq GRCh38/hg38
NM_002524 chr1:g.114709677delC c.344delG p.G115Efs*46 RefSeq GRCh38/hg38
NM_002524.5 chr1:g.114709677delC c.344delG p.G115Efs*46 RefSeq GRCh38/hg38

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
NRAS G115Efs*46 colorectal cancer predicted - resistant Cetuximab Clinical Study - Cohort Actionable In a retrospective analysis, NRAS G115Efs*46 was identified at a frequency of >1% in 3 of 23 patients with metastatic colorectal cancer who did not respond to anti-EGFR therapy (Erbitux (cetuximab), n=12 or Vectibix (panitumumab), n=11), and was associated with a lack of response (p=0.029) to EGFR-targeted therapy (PMID: 32796636). 32796636
NRAS G115Efs*46 colorectal cancer predicted - resistant Panitumumab Clinical Study - Cohort Actionable In a retrospective analysis, NRAS G115Efs*46 was identified at a frequency of >1% in 3 of 23 patients with metastatic colorectal cancer who did not respond to anti-EGFR therapy (Erbitux (cetuximab), n=12 or Vectibix (panitumumab), n=11), and was associated with a lack of response (p=0.029) to EGFR-targeted therapy (PMID: 32796636). 32796636